Carmell Corp. Announces Executive and Director Changes

Ticker: XAGEW · Form: 8-K · Filed: Jan 24, 2025 · CIK: 1842939

Carmell Corp 8-K Filing Summary
FieldDetail
CompanyCarmell Corp (XAGEW)
Form Type8-K
Filed DateJan 24, 2025
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001, $11.50, $150,000
Sentimentneutral

Sentiment: neutral

Topics: management-change, executive-compensation, corporate-governance

TL;DR

Carmell Corp. shakes up leadership and exec pay. New directors in, some officers out.

AI Summary

Carmell Corp. announced on January 20, 2025, changes in its executive team and board of directors. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives. The company, formerly known as Carmell Therapeutics Corp and ALPHA HEALTHCARE ACQUISITION CORP III, is incorporated in Delaware and operates in the Surgical & Medical Instruments & Apparatus industry.

Why It Matters

Changes in leadership and executive compensation can signal shifts in company strategy or performance, impacting investor confidence and future operational direction.

Risk Assessment

Risk Level: medium — Leadership changes and adjustments to compensatory arrangements can introduce uncertainty regarding future strategy and operational stability.

Key Numbers

  • 001-40228 — SEC File Number (Identifies the company's filing history with the SEC.)
  • 86-1645738 — IRS Employer Identification Number (Company's tax identification number.)

Key Players & Entities

  • Carmell Corp. (company) — Registrant
  • Carmell Therapeutics Corp (company) — Former Company Name
  • ALPHA HEALTHCARE ACQUISITION CORP III (company) — Former Company Name
  • Delaware (jurisdiction) — State of Incorporation
  • January 20, 2025 (date) — Date of earliest event reported

FAQ

What specific roles have been affected by the departures and appointments?

The filing indicates the departure of certain officers and directors, and the election of new directors, along with updates to compensatory arrangements for certain officers, but does not specify the exact roles affected in this summary.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on January 20, 2025.

What industry does Carmell Corp. operate in?

Carmell Corp. operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry, with SIC code 3841.

What were Carmell Corp.'s previous names?

Carmell Corp. was formerly known as Carmell Therapeutics Corp and ALPHA HEALTHCARE ACQUISITION CORP III.

Where is Carmell Corp. headquartered?

Carmell Corp. is headquartered at 2403 Sidney Street, Suite 300, Pittsburgh, PA 15203.

Filing Stats: 746 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2025-01-24 17:00:09

Key Financial Figures

  • $0.0001 — ch registered Common Stock, par value $0.0001 per share CTCX The Nasdaq Stock Mar
  • $11.50 — of Common Stock at an exercise price of $11.50 CTCXW The Nasdaq Stock Market LLC
  • $150,000 — ash payments in the aggregate amount of $150,000 to be paid in equal installments over s

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1 Separation and Release of Claims Agreement, dated January 24, 2025, by and between Carmell Corporation and Kendra Bracken-Ferguson 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 24, 2025 By: /s/ Byran J. Cassaday Bryan J. Cassaday Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.